This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Antoniucci, D. Articles by Colombo, A. Search for Related Content PubMed PubMed Citation Articles by Antoniucci, D. Articles by Colombo, A.

A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction

David Antoniucci, MD^*,*, Alfredo Rodriguez, MD, Albrecht Hempel, MD, Renato Valenti, MD^*, Angela Migliorini, MD^*, Federico Vigo, MD, Guido Parodi, MD^*, Carlos Fernandez-Pereira, MD, Guia Moschi, MD^*, Antonio Bartorelli, MD, Giovanni Maria Santoro, MD^*, Leonardo Bolognese, MD^* and Antonio Colombo, MD^||

^* Division of Cardiology, Careggi Hospital, Florence, Italy
Invasive Cardiology Department, Otamendi Hospital, Buenos Aires, Argentina
Bernau Heart Center, Bernau, Germany
Cardiology Department, Monzino Hospital, Milan, Italy
^|| Centro Cuore Columbus, Columbus Hospital, Milan, Italy

View larger version (13K): [in a new window]   Figure 1 Kaplan-Meier curves for the primary end point in the abciximab group and the stenting only group.

View larger version (18K): [in a new window]   Figure 2 (A) Kaplan-Meier curves for the composite of death and reinfarction at six months in the abciximab group and the stenting only group. (B) Kaplan-Meier curves for six-month mortality in patients with and without ST-segment reduction.